

Prevalence of Diabetes Mellitus in Newly Diagnosed Subjects with Sputum +Ve, Pulmonary Tuberculosis and A Literature Review

Bindiya K Pahuja¹, Anant Mohan², Sneha Arora³, Sen Gupta⁴, Rahul Dilwani⁵

How to cite this article:

Bindiya K Pahuja, Anant Mohan, Sneha Arora. Prevalence of Diabetes Mellitus in Newly Diagnosed Subjects with Sputum +Ve, Pulmonary Tuberculosis and A Literature Review. Indian Journal of Diabetes and Endocrinology. 2019;1(2):49-55.

Abstract

The co-morbid diabetic-tuberculosis (DM-TB) patients are often encountered in the clinics. Both the diseases complicate each other at many levels. The idea of the current observational study is to find out the incidence of DM in newly diagnosed TB patients among a study group of 396 patients in Hindu non-tribal and Muslim, low to middle socio economic strata group. And also to review the literature and future strategies to combat such co-morbid conditions.

Keywords: Diabetic-tuberculosis co-morbidity, DM-TB; Diabetes mellitus; Glycemic control; Risk factors for tuberculosis; Tuberculosis; Prevalence.

Introduction

Diabetes mellitus is known to double or triple the incidence of active tuberculosis and increases the risk of tuberculosis treatment adverse outcome, worsen the symptoms and fasten the mortality.^{1,2,3} Approximately 15% cases of pulmonary tuberculosis are linked with DM worldwide.⁴ It is also true that the

tuberculosis increases insulin resistance and causes stress induced hyperglycemia, which may lead to a false diagnosis of diabetes mellitus during the initial phase of active tuberculosis.⁵ The idea of the current observational study is to find out the incidence of DM in newly diagnosed TB patients among a study group of 396 patients in Hindu non-tribal and Muslim, low to middle socio economic strata group. Diagnostic criteria of DM by the American Diabetes Association (ADA) includes a fasting plasma glucose (FPG) level of 126 mg/dL (7.0 μmol/L) or higher, or a 2 hour plasma glucose level of 200 mg/dL (11.1 mmol/L) or higher during a 75g oral glucose tolerance test (OGTT), or a random plasma glucose of 200 mg/dL (11.1 μmol/L) or higher in a patient with classic symptoms of hyperglycemia or hyperglycemic crisis. Whether a hemoglobin A1c (HbA1c) level of 6.5% or higher should be a primary diagnostic criterion or an optional criterion remains a point of controversy.⁶ The socio economic strata of the patient is calculated based on modified Kuppuswamy scale which includes 3 parameters those are the head of families educational status, occupational status and overall aggregate income of the whole family, pooled from all sources. The total score of Kuppuswamy SES ranges from 3-29 and it classifies families into 5 groups, "upper class, upper middle class, lower middle class, upper lower and lower socio-economic class. All the patients in the study group belonged to lower middle class to lower class as per the scale.⁷

Materials and Methods

The study was conducted at two different Centers, namely All India Institute of Medical Sciences, New Delhi and at Chest clinic and TB hospital at Nehru Nagar, New Delhi from September 2018 to January 2019.

Author's Affiliation: ¹Medical Officer, ²Professor and Head, ³PhD Research, Department of Pulmonary Medicine and Sleep Disorders, All India Institute of Medical Sciences, Ansari Nagar, Ansari Nagar East, New Delhi, Delhi 110029, India. ⁴Professor, Department of Pulmonary Medicine, Chest Clinic and T.B. Hospital, Nehru Nagar, Lajpat Nagar, New Delhi 110065, India. ⁵PhD Student, Panjab University, Sector 14, Chandigarh, 160014, India.

Corresponding Author: Bindiya K Pahuja, Medical Officer, Department of Pulmonary Medicine and Sleep Disorders, All India Institute of Medical Sciences, Ansari Nagar, Ansari Nagar East, New Delhi, Delhi 110029, India.

E-mail: bindiyasync@gmail.com

Received on 11.07.2019 Accepted on 31.12.2019

The inclusion criteria were newly diagnosed; smear positive, drug sensitive, pulmonary tuberculosis patients without extra pulmonary involvement, in the age group of 18–60 years. Patients with raised blood glucose levels or with a positive history of diabetes mellitus were included in the study. Patients with any morbidity other than newly diagnosed TB and DM were excluded from the study. A meticulous detailed history was taken including the socioeconomic status, nature of occupation, family history and personal history including the determinants of disease like age, gender, alcohol abuse, cigarette smoking, drug addiction, for both TB and DM, history of present illness, history of co-morbid diseases, and history of diabetes mellitus (type, duration, medication and treatment compliance, and complications). On day 1, the purpose of the study was explained to the patient and informed written consent was obtained. Physical parameters like height, weight, body mass index (BMI), waist circumference; hip circumference and waist-hip ratio were recorded.

Current usage of tobacco or alcohol; number of cigarettes smoked per day and number of years of smoking; average daily quantity and frequency of alcohol consumed were ascertained. The height, weight, waist circumference and hip circumference were measured. BMI was also measured through Bio-scale. The participants were called the very next day after overnight fasting. The fasting blood glucose levels of the patient were measured using a standardized glucometer. Patients with abnormal fasting blood sugar values or presence of two or more risk factors were subjected to further blood investigations and sent to the laboratory in the center itself for blood investigations including PP blood sugar and HbA1c. Data were statistically analyzed.

Results

A total of 396 patients were screened. Of these, 28 patients were already known to have Type II diabetes and were on anti-hyperglycemic treatment. Additional 26 patients were detected

having increased blood glucose levels and glycosylated hemoglobin (HbA1C) at the time of screening (Table 1). These patients were unaware of their raised blood glucose levels and only 7 out of 26 patients gave a positive family history of DM. Patients were considered to be diabetic if they had fasting plasma glucose > (126 mg/dl). Or with a glucose tolerance test, two hours after the oral dose of plasma glucose > (200 mg/dl) or Glycosylated hemoglobin (HbA1c) of greater than 6.5%.⁸ Among these 54 diabetic patients, 24 were male and 30 were female. Patients of DM who developed TB were all found to have poor glycemic control. In the present study all the 24 males fall in working category involved in semi-skilled to unskilled works. Many of the males were into tobacco chewing, smoking and were having regular alcohol intake. Among all the males 18 of the males were alcoholics, 12 were found to be smoking tobacco, 12 were smokeless tobacco chewers and none of them was a drug addict. All the 30 females were non-alcoholic and non-tobacco chewers. Only 4 of the females were enrolled in unskilled household activities, rest of the females was householders.

The present study has found a 13.6% prevalence of diabetes mellitus in newly diagnosed TB patients. This study has not found any significant association between patients mean weight, height or BMI with the outcome of disease, in the literature also no such association has been found.¹³ This study has reported a significant number of male subjects involved in some form of substance abuse. The current study does not, have sufficient data to establish sex predilection among the DM-TB patients. In the current study the mean age of (DM-TB) co-morbid group was (43.14 ± 9.75) that fall in fourth and fifth decade of life. The result is also consistent with the study conducted in Mexico on 561 DM-TB subjects with a mean age group of 53 years, the DM-TB patients are found to be older than patients having TB alone.⁸ The mean weight and height of the patients in DM-TB patients is found to be (48.88 ± 11.67) and mean height is calculated to be (157 ± 5.96) which means DM-TB are less obese than patients of DM alone, as TB is known to cause anorexia in these patients (Figs. 2-9).

Table 1: Presenting the mean and standard deviation of fasting blood glucose, PP and HbA1c in the study group

DM + TB patients	Age (years)	Weight (kg)	Height (cm)	Fasting (mg/dL)	PP (mg/dL)	HbA1C
Study group (All 54 patients)	43.14 ± 9.75	48.88 ± 11.67	157 ± 5.96	136 ± 40.71	178.38 ± 54.77	7.33 ± 1.22
Known cases of DM (28 patients)	44.92 ± 9.86	52.10 ± 13.15	156.60 ± 5.47	132.42 ± 36.93	159.92 ± 46.26	7.28 ± 1.47
Newly diagnosed DM (26 patients)	41.23 ± 9.45	45.42 ± 8.81	157.42 ± 6.53	141.11 ± 44.71	198.26 ± 57.06	7.38 ± 0.90




Fig. 1: The study methodology flow chart.




Fig. 2: Fasting blood glucose levels at baseline of the study group.




Fig. 3: HbA1c levels in the study group at baseline.




Fig. 4: Sex distribution graph in DM-TB patients.




Fig. 5: BMI distribution graph of DM-TN patients.




Fig. 6: Age distribution graph of DM-TB patients




Fig. 7: Height distribution graph of DM-TB patients.




Fig. 8: Weight distribution graph of DM-TB patients.




Fig. 9: PP blood glucose levels at baseline of the study group.

Discussion

DM is linked to TB in 15% of cases worldwide from other countries like Indonesia, Malaysia, Saudi Arabia, Taiwan and Mexico.⁹⁻¹² A large number of studies have associated DM with an increased risk of relapse rates in TB patients, raised blood glucose levels are also a cause of treatment failure and high mortality in TB patients.¹⁴ Diabetes mellitus is an important risk factor for reactivation of tuberculosis.¹⁵ A systemic review says that DM triples the risk of developing tuberculosis and worsens the symptoms to a significant patient discomfort.⁷

The Relation of Glycemic Control and Development of Tuberculosis

The hazard of TB in diabetic patients with good glycemic control (FPG 130 mg/dl) did not differ

significantly from that in non-diabetic individuals.⁹ In the linear dose-response analysis, by one study the hazard of TB increased with poor glycemic control. Assuming the observed association between glycemic control and TB was found to be causal.^{16,17}

Tuberculosis patients with DM show more pronounced clinical presentation in terms of symptoms, weight loss, fever, dyspnea, and night sweats.¹⁸ Radiologically also DM-TB patients have more extensive lesions, more often have multilobar disease, more frequently present with cavitation and with predominant involvement of the Lower-lung.¹⁹ The bacterial burden at presentation is higher in patients with DM as DM can lead to multiple complications like increased susceptibility to infection, hyperglycemia and insulinopenia which may further alter the function of lymphocytes and

macrophages.^{20,21} On the other hand tuberculosis can also cause transient hyperglycemia by causing impaired glucose tolerance. Which is a risk factor for occurrence of DM.²² Therefore in the current study the newly diagnosed 26 patients may or may not have developed true Diabetes mellitus. The raised blood glucose levels could be due to transient hyperglycaemia caused by tuberculosis infection.¹⁶ Therefore glucose levels should be rechecked after 4 weeks of start of ATT, or after the patient is afebrile to establish a frank diagnosis of DM.^{4,1,23}

A person with tuberculosis has significantly higher mortality if the person also has DM.²¹ Studies have shown that, in patients with pulmonary tuberculosis the mortality rate is 6.5–6.7 times higher than patients of Tuberculosis alone.²⁴ In a study by Baker et al. it has been concluded that patients with tuberculosis and DM have a nearly 4-fold higher risk of relapse than do those with tuberculosis alone.²⁵

Cigarette smoking is known to be an independent risk factor for tuberculosis. The role that cigarette smoke plays in the pathogenesis of tuberculosis is related to ciliary dysfunction, and majorly due to altered immune response. Many systemic reviews and meta-analyses of observational studies have shown an unfavorable association between the global epidemics of tuberculosis and smoking.²⁶

Literature in the past has shown a significant association between alcohol consumption and use of tobacco in the prevalence of TB in diabetes.⁴ P Alcohol abuse has also been associated with tuberculosis as an independent risk factor. It has been estimated by literature in the past that approximately 10% of all tuberculosis cases are attributable to alcohol use.²⁷ Alcohol use disorder or AUD is a chronic, relapsing brain disease characterized by an impaired ability to stop or control alcohol use despite adverse social, occupational, or health consequences. The prevalence of AUD among tuberculosis patients varies among different ethnic groups.²⁸ The association between alcohol use and tuberculosis has been known since ages, but it is not known if the increased risk of tuberculosis is due to the use of alcohol per say or because of the sequel of AUD, which attributes to liver damage and nutritional deficiency, or may be due to social factors, such as crowding, malnutrition, homelessness, and imprisonment, independently of the alcohol consumption.²⁹

Conclusion

With the increase in life expectancy, improvements in provision of health services worldwide, progressing sedentary life styles, the absolute numbers of cases of diabetes is likely to increase exponentially in future. The World Health Organization (WHO) collaborative framework for tuberculosis and DM currently recommends bidirectional screening—screening for DM in all patients with tuberculosis and vice versa.³⁰ The collaborative framework for care and control of TB and DM has already started many pilot studies and projects globally. The WHO Non-communicable disease global action plan 2013–2020 aims to reduce the impact of diabetes under the new sustainable development goals which also puts a spotlight on TB-DM cases.²² Glycemic control in DM patients may also be an important strategy for global TB control. It is hypothesized that adequate management of blood glucose would reduce the risk of TB among diabetic patients.⁹ Further studies are needed to differentiate true diabetes mellitus patients from patients having transient hyperglycemia during early stage of tuberculosis.

Future Strategies

Metformin an oral hypoglycemic drug is found to have an inhibitory effect on cellular mitochondrial Complex I, inhibition of which has been found to alter the cellular energy status in immune cells. It promotes phagocytosis, phagolysosome fusion and autophagy in macrophages. Metformin may stimulate macrophages to produce large number of nitrous oxide for oxidative killing and promote higher bactericidal capacity attributed to increased mitochondrial reactive oxidative species (ROS) production required for bacterial killing.³¹ Approximately 90% of the newly diagnosed sputum-positive patients are sensitive to isoniazid (H) and rifampicin (R), adding the drug metformin would have a beneficial effect in the early killing of intracellular bacteria by influencing the host immunity.³² As per the study it should also reduce the overall burden on the health care system.^{32,33}

References

1. Boillat-Blanco N, Ramaiya KL, Mganga M, et al. Transient Hyperglycemia in Patients With Tuberculosis in Tanzania: Implications for Diabetes Screening Algorithms. *J Infect Dis.* 2016 Apr 1;213(7):1163–72.

2. Baker MA, Harries AD, Jeon CY, et al. The impact of diabetes on tuberculosis treatment outcomes: A systematic review. *BMC Med* 2011;9:81.
3. Wagnew F, Eshetie S, Alebel A, et al. Meta-analysis of the prevalence of tuberculosis in diabetic patients and its association with cigarette smoking in African and Asian countries. *BMC Res Notes* [Internet]. 2018 Dec [cited 2019 Jul 6];11(1). Available from: <https://bmcresnotes.biomedcentral.com/articles/10.1186/s13104-018-3390-x>
4. Silva DR, Muñoz-Torrico M, Duarte R, et al. Risk factors for tuberculosis: Diabetes, smoking, alcohol use, and the use of other drugs. *J Bras Pneumol* 2018 Apr;44(2):145–52.
5. Dungan KM, Braithwaite SS, Preiser JC. Stress hyperglycaemia. *Lancet* 2009;373:1798–07.
6. American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care*. 2010 Jan 1;33(Supplement_1):S62–9.
7. Mohd Saleem S, Community Medicine. Modified Kuppuswamy socioeconomic scale updated for the year 2019. *Indian J Forensic Community Med* 2019 Apr 28;6(1):1–3.
8. A. Ponce-de-Leon, M.L. Garcia-Garcia, et al., Tuberculosis and diabetes in southern Mexico, *Diabetes Care* 2004;27:1584–90.
9. Singla R, Khan N, Al-Sharif N, et al. Influence of diabetes on manifestations and treatment outcome of pulmonary TB patients. *Int J Tuberc Lung Dis* 2006;10:74–9. [PubMed: 16466041].
10. Alisjahbana B, Sahiratmadja E, Nelwan EJ, et al. The effect of Type 2 diabetes mellitus on the presentation and treatment response of pulmonary tuberculosis. *Clin Infect Dis* 2007;45:428–35. [PubMed: 17638189].
11. Chang JT, Dou HY, Yen CL, et al. Effect of type 2 diabetes mellitus on clinical severity and treatment outcome in patients with pulmonary tuberculosis: A potential role in the emergence of multi-drug resistance. *J Formos Med Assoc* 2011;110(6):372–81. [PubMed: 21741005].
12. Gupta A, Shah A. Tuberculosis and Diabetes: An Appraisal. *Ind J Tub* 2000;47(3):2–8.
13. Jain MK, Baghel PK, Agrawal R. Study of impaired glucose tolerance in pulmonary tuberculosis. *Indian J Community Med* 2006;31(3):137–9.
14. Jeon CY, Murray MB. Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. *PLoS Med*. 2008 Jul 15;5(7):e152.
15. Solá E, Rivera C, Mangual M, et al. Diabetes mellitus: an important risk factor for reactivation of tuberculosis. *Endocrinol Diabetes Metab Case Rep* [Internet]. 2016 Jul 29 [cited 2019 Jul 6];2016. Available from: <https://edm.bioscientifica.com/view/journals/edm/2016/1/EDM16-0035.xml>
16. Lee P-H, Fu H, Lai T-C, et al. Glycemic Control and the Risk of Tuberculosis: A Cohort Study. Metcalfe JZ, editor. *PLOS Med* 2016 Aug 9;13(8):e1002072.
17. Leegaard A, Riis A, Kornum JB, et al. Diabetes, Glycemic Control, and Risk of Tuberculosis: A population-based case-control study. *Diabetes Care* 2011 Dec 1;34(12):2530–5.
18. Dooley KE, Chaisson RE. Tuberculosis and diabetes mellitus: convergence of two epidemics. *Lancet Infect Dis*. 2009 Dec;9(12):737–746. doi:[http://dx.doi.org/10.1016/S1473-3099\(09\)70282-8](http://dx.doi.org/10.1016/S1473-3099(09)70282-8).
19. Muñoz-Torrico M, Caminero Luna J, Migliori GB, et al. Comparison of bacteriological conversion and treatment outcomes among MDR-TB patients with and without diabetes in Mexico: Preliminary data. *Rev Port Pneumol* 2017 Jan-Feb;23(1):27–30.
20. Workneh MH, Bjune GA, Yimer SA. Prevalence and associated factors of tuberculosis and diabetes mellitus comorbidity: A systematic review. *PLoS One* 2017;12(4):e0175925. <https://doi.org/10.1371/journal.pone.0175925>.
21. Jiménez-Corona ME, Cruz-Hervert LP, García-García L, et al. Association of diabetes and tuberculosis: Impact on treatment and post-treatment outcomes. *Thorax* 2013 Mar;68(3):214–20.
22. World Health Organization [homepage on the Internet]. Geneva: World Health Organization; c2016 [cited 2016 Dec 1]. Tuberculosis and diabetes. [Adobe Acrobat document, 2p.]. Available from: http://www.who.int/tb/publications/diabetes_tb.pdf.
23. Raj P, Prakash R, Mishra G, et al. Prevalence of smear-positive pulmonary tuberculosis in different ethnic groups in India: Evaluation of public health. *Public Health* 2012 Apr;126(4):295–9.
24. Oursler KK, Moore RD, Bishai WR, et al. Survival of patients with pulmonary tuberculosis: clinical and molecular epidemiologic factors. *Clin Infect Dis* 2002;34(6):752–9. <https://doi.org/10.1086/338784>.
25. Restrepo BI. Diabetes and tuberculosis. *Microbiol Spectr* 2016;4(6):1–19.
26. Bates MN, Khalakdina A, Pai M, et al. The risk of tuberculosis from exposure to tobacco smoke: A systematic review and meta-analysis. *Arch Intern Med* 2007;167(4):335–42. <https://doi.org/10.1001/archinte.167.4.335>.
27. Rehm J, Samokhvalov AV, Neuman MG, et al. The association between alcohol use,

- alcohol use disorders and tuberculosis (TB). A systematic review. *BMC Public Health*. 2009;9:450. <https://doi.org/10.1186/1471-2458-9-450>.
28. Shin SS, Mathew TA, Yanova GV, et al. Alcohol consumption among men and women with tuberculosis in Tomsk, Russia. *Cent Eur J Public Health* 2010;18(3):132-8.
 29. Molina PE, Happel KI, Zhang P, et al. Focus on: Alcohol and the immune system. *Alcohol Res Health* 2010;33(1-2):97-108.
 30. Pizzol D, Di Gennaro F, Chhaganlal KD, et al. Tuberculosis and diabetes: Current state and future perspectives. *Trop Med Int Health* 2016;21(6):694-02.
 31. Tan HY, Wang N, Li S, et al. The reactive oxygen species in macrophage polarization: Reflecting its dual role in progression and treatment of human diseases. *Oxid Med Cell Longev* 2016;2016:1-16.
 32. Padmapriyadarsini C, Bhavani PK, Natrajan M, et al. Evaluation of metformin in combination with rifampicin containing antituberculosis therapy in patients with new, smear-positive pulmonary tuberculosis (METRIF): study protocol for a randomised clinical trial. *BMJ Open*. 2019 Mar;9(3):e024363.
 33. Marupuru S, Senapati P, Pathadka S, et al. Protective effect of metformin against tuberculosis infections in diabetic patients: an observational study of south Indian tertiary healthcare facility. *Braz J Infect Dis* 2017 May;21(3):312-6.
